In addition, we hypothesize that a “good” mutant RUNX1 with a higher binding affinity to DNA could counteract a leukemia-causing RUNX1 mutant and have an enhanced RUNX1 activity for hematopoiesis. This evidence concerns the gene RUNX1 and leukemia.